New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
07:02 EDTCHTPChelsea Therapeutics announces expiration of HSR waiting period
Chelsea Therapeutics announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the previously announced Agreement and Plan of Merger, dated as of May 7, by and among Chelsea, H. Lundbeck A/S, and Charlie Acquisition Corp., an indirect wholly owned subsidiary of Lundbeck. As announced on May 23, Lundbeck has commenced a tender offer to purchase all of the outstanding shares of Chelsea for $6.44 per share in cash and one contingent value right that may pay up to an additional $1.50 per share upon achievement of certain net sales milestones, for a total potential consideration of up to $7.94 per share, or an aggregate of $658M on a fully diluted basis. Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the closing of the Offer and the Merger. The Offer and the Merger remain subject to other customary closing conditions.
News For CHTP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CHTP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use